|Security||CBPO / China Biologic Products, Inc. (16938C106)|
|Industry||Biological Products, Except Diagnostic Substances (Biotech)|
|Institutional Shares||2,810,243 - 10.32%|
|Common Shares Outstanding||27,238,357 shares (as of 2017-06-30)|
|Institutional Value||$ 124,246,000 USD|
Institutional Stock Ownership and Shareholders
China Biologic Products, Inc. (NASDAQ:CBPO) has 13 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,810,243 shares.
Largest shareholders include
Smallcap World Fund Inc, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Group LTD, Standard Life Investments LTD, Manning & Napier Advisors Llc, SPQ Asia Capital Ltd, Veritas Asset Management LLP, Strs Ohio, and R&F Capital Advisors LP.
China Biologic Products, Inc. (NASDAQ:CBPO) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|BlackRock Investment Management, LLC||5,501||2,391||-56.54||685||257||-62.48|
|R&F Capital Advisors LP||5,258||4,218||-19.78||565||422||-25.31|
|Acrospire Investment Management LLC||184||0||-100.00||21||0||-100.00|
|BlackRock Japan Co. Ltd||949||470||-50.47||118||51||-56.78|
|Veritas Asset Management LLP||0||10,000||0||993|
|MANNING & NAPIER ADVISORS LLC||82,325||71,755||-12.84||8,241||8,114||-1.54|
|BlackRock Group LTD||176,262||205,356||16.51||21,941||22,080||0.63|
|BlackRock Institutional Trust Company, N.A.||199,382||306,890||53.92||24,819||32,997||32.95|
|SPQ Asia Capital Ltd||34,324||21,824||-36.42||3,437||2,468||-28.19|
|BlackRock Fund Advisors||357,390||380,241||6.39||44,488||40,884||-8.10|
|SMALLCAP WORLD FUND INC||1,664,923|
|BARING ASSET MANAGEMENT Ltd||166,774||0||-100.00||18,862||0||-100.00|
|Standard Life Investments LTD||134,229||131,045||-2.37||13,436||14,821||10.31|
|CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC.||363,190||0||-100.00||33,511||0||-100.00|
Related News Stories
Mabpharm Limited, a Taizhou biotech, will IPO in Hong Kong, the eleventh pre-revenue China biopharma to be approved to list there. Mabpharm is developing a portfolio of nine biosimilars, which it hopes will prove to be biobetters. Three of the candidates are in Phase III trials. They were initially discovered by Sinomab, which spun out Mabpharm to develop the drugs, while Sinomab continues to focus on its CRO/CMO operations. (1-0)
China Biologic Products Holdings, Inc. (CBPO - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 2.7% in the past one-month time frame.
China Biologic Products, Inc. (NASDAQ:CBPO) Q2 2018 Earnings Conference Call August 6, 2018 7:30 AM ET
CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products (NASDAQ:CBPO), one of China's top five plasma-based biopharmas. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding. Headquartered in Beijing, CBPO operates plasma-gathering facilities and offers 20 plasma-based products. The offer, priced at $110 per share, represents a P/E ratio of 37 based on the past 12 months, but only 16. (76-2)
(Reuters) - A unit of Chinese investment firm CITIC Capital Holdings Ltd has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc (CBPO.O). (8-1)
as of ET